Browse PPBP

Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002283 neutrophil activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002523 leukocyte migration involved in inflammatory response
GO:0002576 platelet degranulation
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006887 exocytosis
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0034219 carbohydrate transmembrane transport
GO:0035428 hexose transmembrane transport
GO:0036230 granulocyte activation
GO:0040017 positive regulation of locomotion
GO:0042119 neutrophil activation
GO:0042742 defense response to bacterium
GO:0043299 leukocyte degranulation
GO:0043312 neutrophil degranulation
GO:0045055 regulated exocytosis
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0071621 granulocyte chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0098542 defense response to other organism
GO:1904659 glucose transmembrane transport
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005355 glucose transmembrane transporter activity
GO:0008009 chemokine activity
GO:0008083 growth factor activity
GO:0015144 carbohydrate transmembrane transporter activity
GO:0015145 monosaccharide transmembrane transporter activity
GO:0015149 hexose transmembrane transporter activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
GO:0051119 sugar transmembrane transporter activity
GO:1901476 carbohydrate transporter activity
Cellular Component GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPBP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPBP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPBP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1070.834
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5130.529
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5450.431
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.3530.0232
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.6620.0924
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.9490.261
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.130.201
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.8670.483
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.1130.438
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0790.496
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0690.975
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.090.789
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPBP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPBP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPBP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPBP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPBP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPBP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPBP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPBP
Namepro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
Aliases SCYB7; TGB; NAP-2-L1; LA-PF4; MDGF; LDGF; Beta-TG; CTAP3; CXCL7; b-TG1; TGB1; CTAPIII; platelet basic protei ......
Chromosomal Location4q12-q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPBP collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PPBP.
ID Name Drug Type Targets #Targets
DB03635Ethanesulfonic AcidSmall MoleculePPBP1
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141